Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
Humans
Hodgkin Disease
/ drug therapy
Brentuximab Vedotin
/ therapeutic use
Cost-Benefit Analysis
Hematopoietic Stem Cell Transplantation
Doxorubicin
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bleomycin
/ therapeutic use
Vinblastine
/ therapeutic use
Dacarbazine
/ therapeutic use
Transplantation, Autologous
Brentuximab vedotin
Economic evaluation
Hodgkin lymphoma
Systematic review
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
14
04
2023
accepted:
23
08
2023
medline:
1
11
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
This study aimed to systematically review and critically appraise cost-effectiveness studies on Brentuximab vedotin (BV) in patients with Hodgkin lymphoma (HL). The PubMed, Scopus, Web of Science core collection, and Embase databases were searched until July 3, 2022. We included published full economic evaluation studies on BV for treating patients with HL. The methodological quality of the studies was assessed using the Quality of Health Economic Studies (QHES) checklist. Meanwhile, we used qualitative synthesis to analyze the findings. We converted the incremental cost-effectiveness ratios (ICERs) to the value of the US dollar in 2022. Eight economic evaluations met the study's inclusion criteria. The results of three studies that compared BV plus doxorubicin, vinblastine, and dacarbazine (BV + AVD) front-line therapy with doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD) showed that BV is unlikely to be cost-effective as a front-line treatment in patients advanced stage (III or IV) HL. Four studies investigated the cost-effectiveness of BV in patients with relapsed or refractory (R/R) HL after autologous stem cell transplantation (ASCT). BV was not cost-effective in the reviewed studies at accepted thresholds. In addition, the adjusted ICERs ranged from $65,382 to $374,896 per quality-adjusted life-year (QALY). The key drivers of cost-effectiveness were medication costs, hazard ratio for BV, and utilities. Available economic evaluations show that using BV as front-line treatment or consolidation therapy is not cost-effective based on specific ICER thresholds for patients with HL or R/R HL. To decide on this orphan drug, we should consider other factors such as existence of alternative treatment options, clinical benefits, and disease burden.
Identifiants
pubmed: 37656182
doi: 10.1007/s00228-023-03557-6
pii: 10.1007/s00228-023-03557-6
doi:
Substances chimiques
Brentuximab Vedotin
7XL5ISS668
Doxorubicin
80168379AG
Bleomycin
11056-06-7
Vinblastine
5V9KLZ54CY
Dacarbazine
7GR28W0FJI
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1443-1452Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Delea TE, Sharma A, Grossman A et al (2019) Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. J Med Econ 22(2):117–130
doi: 10.1080/13696998.2018.1542599
pubmed: 30375910
Huang J, Pang WS, Lok V et al (2022) Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol 15(1):57
doi: 10.1186/s13045-022-01281-9
pubmed: 35546241
pmcid: 9097358
ACS About Hodgkin Lymphoma (2022) [Internet]; [cited 2022 Aug 9]. American Cancer Society. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8649.00.pdf
Huntington SF, Von Keudell GR, Davidoff AJ et al (2018) Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma. J Clin Oncol 36(15)
Connors JM, Radford JA (2018) Brentuximab vedotin for stage III or IV Hodgkin’s lymphoma. N Engl J Med 378(16):1560–1561
pubmed: 29669231
Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 374(25):2419–2429
doi: 10.1056/NEJMoa1510093
pubmed: 27332902
pmcid: 4961236
Ansell SM (2016) Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91(4):434–442
doi: 10.1002/ajh.24272
pubmed: 27001163
FDA Products on BLA 125388 (2011) [Internet]; [cited 2022 Aug 9]. US Food and Drug Administration. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388
Street Insider. Seattle Genetics (SGEN) Granted Approval of ADCETRIS (Brentuximab Vedotin) (2017; [Internet]; [cited 2022 Aug 9]. Street Insider. Available from: https://www.streetinsider.com/Corporate+News/Seattle+Genetics+%28SGEN%29+Granted+Approval+of+ADCETRIS+%28Brentuximab+Vedotin%29/13125348.html
Younes A, Connors JM, Park SI et al (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14(13):1348–1356
doi: 10.1016/S1470-2045(13)70501-1
pubmed: 24239220
Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183
doi: 10.1200/JCO.2011.38.0410
pubmed: 22454421
pmcid: 3646316
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7)
doi: 10.1371/journal.pmed.1000097
pubmed: 19621072
pmcid: 2707599
The Campbell and Cochrane Economics Methods Group (CCEMG) & Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre) (2019) [Internet]; [cited 2022 Aug 9]. CCEMG – EPPI-Centre Cost Converter. Available from: https://eppi.ioe.ac.uk/costconversion/
Ofman JJ, Sullivan SD, Neumann PJ et al (2003) Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 9(1):53–61
pubmed: 14613362
Hui L, von Keudell G, Wang R et al (2017) Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 123(19):3763–3771
doi: 10.1002/cncr.30818
pubmed: 28640385
Large S, Hettle R, Balakumaran A et al (2019) Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin’s lymphoma: a United States payer perspective. J Med Econ 22(1):16–25
doi: 10.1080/13696998.2018.1534738
Babashov V, Begen MA, Mangel J et al (2017) Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma. Cancer 24(1):e6–e14
Raymakers AJN, Costa S, Cameron D et al (2020) Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis. BMC Cancer 20(1)
Vijenthira A, Chan K, Cheung MC et al (2020) Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. Lancet Haematol 7(2):E146–E156
doi: 10.1016/S2352-3026(19)30218-2
pubmed: 31948928
Parker C, Woods B, Eaton J et al (2017) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland [Article]. J Med Econ 20(1):8–18
doi: 10.1080/13696998.2016.1219358
pubmed: 27472034
Hanly P, Soerjomataram I, Sharp L (2015) Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in E urope. Int J Cancer 136(4):E136–E145
doi: 10.1002/ijc.29105
pubmed: 25066804
Cote S, Gaudig M, Nielsen S et al (2015) Challenges for assessing the economic value of orphan drugs-a literature review of current and alternative approaches. Value Health 18(7):A681
doi: 10.1016/j.jval.2015.09.2026
Stewart G, Eddowes L, Hamerslag L et al (2014) The impact of NICE’s end-of-life threshold on patient access to new cancer therapies in England and Wales. Value Health 17(3):A6
doi: 10.1016/j.jval.2014.03.041
NICE Appraising lifeextending, end of life treatments (2009) [Internet]; [cited 2022 Aug 9]. National Institute for Health and Care Excellence. Available from: https://www.nice.org.uk/guidance/gid-tag387/documents/appraising-life-extending-end-of-life-treatments-paper2